• Logo
  • SBMUJournals

Clinical implications of peripheral CD3+CD69+ T-cell and CD8+CD28+ T-cell proportions in patients prior to radical prostatectomy

Yu Zhang, Ziye Zhang, Lina Zhang, Sheng Zhao, Jing Zhao, Qing Ye, Yingli Gao, Chenyi Jiang, Di Cui, Shujie Xia, Bangmin Han, Yifeng Jing
183

Views


Abstract

Purpose: To investigate the clinical implications of CD3+CD69+ T-cells and CD8+CD28+ T-cells in the peripheral blood of patients prior to radical prostatectomy.

Materials and Methods: A total of 91 prostate cancer (PCa) patients and 50 benign prostatic hyperplasia (BPH) patients were enrolled from January 2016 to December 2017. The proportions of CD3+CD69+ T-cells and CD8+CD28+ T-cells in the peripheral blood of PCa and BPH patients were detected by flow cytometry, and the association of these T-cell populations with pathological Grade Group and pathological TNM classification was evaluated. Data analysis was performed with SAS version 9.4 software.

Results: The proportions of CD3+CD69+ and CD8+CD28+ T-cells in peripheral blood were higher in PCa patients than those in BPH patients. Multivariate analysis identified a higher CD3+CD69+ T-cell proportion as a risk factor for PCa (odds ratio (OR)=4.783, P=0.0013), but the diagnostic efficacy of the CD3+CD69+ T-cell proportion (area under the curve (AUC)=0.6833, P=0.0003) for PCa was still inferior to that of the tPSA level (AUC=0.7531, P<0.0001). The AUCs for CD3+CD69+ T-cell and CD8+CD28+ T-cell proportions for PCa were 0.6959 (P=0.0372) and 0.6935 (P=0.0395), respectively, among men with tPSA levels of 4.0-10.0 ng/ml. A lower CD3+CD69+ T-cell proportion was associated with higher pathological Grade Group (P=0.0074).

Conclusion: The proportions of CD3+CD69+ T-cells and CD8+CD28+ T-cells in peripheral blood are potential diagnostic indicators for PCa. The preoperative proportion of CD3+CD69+ T-cells in peripheral blood may have prognostic value in terms of the pathological Grade Group in PCa


References

Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.

Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Related Cancer 2017;24(12):T297-T310.

Wang ZK, Yang B, Liu H, et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 2012; 61: 911-916.

Krupnick AS, Kreisel D, Szeto WY, et al. Multiparameter flow cytometric approach for simultaneous evaluation of T lymphocyte-endothelial cell interactions. Cytometry 2001; 46: 271-280.

Frydecka I, Kosmaczewska A, Bocko D, et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 2004; 90: 2042-2048.

Bocko D, Kosmaczewska A, Ciszak L, Teodorowska R and Frydecka I. CD28 costimulatory molecule--expression, structure and function. Arch Immunol Ther Exp (Warsz) 2002; 50: 169-177.

Martin P, Gomez M, Lamana A, et al. CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol 2010; 30: 4877-4889.

Martin P and Sanchez-Madrid F. CD69: an unexpected regulator of TH17 cell-driven inflammatory responses. Sci Signal 2011; 4: pe14.

Esplugues E, Sancho D, Vega-Ramos J, et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003; 197: 1093-1106.

Yang W, Jia X, Su Y and Li Q. Immunophenotypic characterization of CD45RO+ and CD45RA+ T cell subsets in peripheral blood of peripheral T cell lymphoma patients. Cell Biochem Biophys 2014; 70: 993-997.

Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629.

Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15: e484-e492.

Lee DJ, Ahmed HU, Moore CM, Emberton M and Ehdaie B. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep 2014; 15: 390.

Yang Z, Yu L and Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016; 28: 65-71.

Katafigiotis I, Tyritzis SI, Stravodimos KG, et al. Zinc alpha2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int 2012; 110: E688-693.

Starska K, Glowacka E, Kulig A, Lewy-Trenda I, Brys M and Lewkowicz P. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II. Folia Histochem Cytobiol 2011; 49: 593-603.

Epstein JI, Pound CR, Partin AW and Walsh PC. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998; 160: 97-100; discussion 101.

Pins MR, Fiadjoe JE, Korley F, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prostate Cancer Prostatic Dis 2004; 7: 243-248.

Lee H, Jeong SJ, Hong SK, Byun SS, Lee SE and Oh JJ. High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. World J Urol 2016; 34: 821-827.




DOI: http://dx.doi.org/10.22037/uj.v0i0.5103

Refbacks

  • There are currently no refbacks.